135P Management of sarcomas in adolescents and young adults (AYAs) in Spain

type, the negative association of PPI use on treatment response was not significant.Additionally, there was statistically significant negative association between the use PPIs and adverse events (p < 0.05). Conclusions:We demonstrated that the concomitant use of PPIs at baseline with pazopanib in patients affected by STS is associated with a detrimental effect on OS and response to treatment.However, results show a potential protective effect of PPIs against adverse events.The potential drug-drug interaction between PPIs and pazopanib warrants careful consideration in treatment planning and patient management to optimize therapeutic efficacy, safety and outcomes.